Hisun Cooperates With MNCs To Tap International Market
This article was originally published in PharmAsia News
Executive Summary
After getting Eli Lilly's technology transfer on processing capreomycin raw material, Zhejiang Hisun Pharmaceutical is building a production line capable of producing 3 million to 5 million doses of capreomycin annually. The company will complete its registration and Good Manufacturing Practices authentication in China this year. It is also preparing documentation for World Health Organization registration and approval, and may be WHO's only supplier of capreomycin in China. Its doses will be ready for the international market in two years. Hisun has a joint venture with Xinghai Pharmaceutical and Spain Farmaprojects S. A. that taps on the latter's overseas sales channels. Besides the capreomycin collaboration, Lilly may consider acquiring Hisun's products still in development as well as use the Chinese firm to manufacture its drugs. (Click here for more - Chinese Language)
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.